El Sahly H |
MF59™ as a vaccine adjuvant: a review of safety and immunogenicity. |
2010 |
Expert Rev Vaccines |
pmid:20923265
|
Waddington C et al. |
Open-label, randomised, parallel-group, multicentre study to evaluate the safety, tolerability and immunogenicity of an AS03(B)/oil-in-water emulsion-adjuvanted (AS03(B)) split-virion versus non-adjuvanted whole-virion H1N1 influenza vaccine in UK children 6 months to 12 years of age. |
2010 |
Health Technol Assess |
pmid:20923610
|
Iannitti T and Palmieri B |
An update on the therapeutic role of alkylglycerols. |
2010 |
Mar Drugs |
pmid:20948908
|
Michael-Jubeli R et al. |
High-temperature gas chromatography-mass spectrometry for skin surface lipids profiling. |
2011 |
J. Lipid Res. |
pmid:20952798
|
Esposito S et al. |
An open-label, randomized clinical trial assessing immunogenicity, safety and tolerability of pandemic influenza A/H1N1 MF59-adjuvanted vaccine administered sequentially or simultaneously with seasonal virosomal-adjuvanted influenza vaccine to paediatric kidney transplant recipients. |
2011 |
Nephrol. Dial. Transplant. |
pmid:20974645
|
De Luca C and Valacchi G |
Surface lipids as multifunctional mediators of skin responses to environmental stimuli. |
2010 |
Mediators Inflamm. |
pmid:20981292
|
Madhun AS et al. |
An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers. |
2010 |
Vaccine |
pmid:21034828
|
Packwood DM and Phillips LF |
A stochastic, local mode study of neon-liquid surface collision dynamics. |
2011 |
Phys Chem Chem Phys |
pmid:21042647
|
Bate J et al. |
Immunogenicity of pandemic (H1N1) 2009 vaccine in children with cancer in the United Kingdom. |
2010 |
Clin. Infect. Dis. |
pmid:21067352
|
Smentek L and Hess BA |
Compelling computational evidence for the concerted cyclization of the ABC rings of hopene from protonated squalene. |
2010 |
J. Am. Chem. Soc. |
pmid:21080653
|
Bertolino A et al. |
Polyisoprenoid amphiphilic compounds as inhibitors of squalene synthesis and other microsomal enzymes. |
1978 |
Biochim. Biophys. Acta |
pmid:210830
|
Lin FY et al. |
Mechanism of action and inhibition of dehydrosqualene synthase. |
2010 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:21098670
|
Ali NA et al. |
Essential oil composition of leaves of Stachys yemenensis obtained by supercritical COâ‚‚. |
2010 |
Nat. Prod. Res. |
pmid:21104527
|
Walker WT and Faust SN |
Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine. |
2010 |
Expert Rev Vaccines |
pmid:21105775
|
Wu J et al. |
Superior protection provided by a single dose of MF59-adjuvanted whole inactivated H5N1 influenza vaccine in type 1 diabetic mice. |
2011 |
Arch. Virol. |
pmid:21110049
|
Kato S et al. |
Clinical evaluation of fullerene-C60 dissolved in squalane for anti-wrinkle cosmetics. |
2010 |
J Nanosci Nanotechnol |
pmid:21137794
|
Andrews N et al. |
Age-specific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in England. |
2011 |
J. Infect. Dis. |
pmid:21148494
|
Kajaste-Rudnitski A et al. |
Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individuals. |
2011 |
AIDS |
pmid:21150561
|
Javelle E et al. |
Delayed focal lipoatrophy after AS03-adjuvanted influenza A (H1N1) 2009 vaccine. |
2011 |
Vaccine |
pmid:21172376
|
Montana M et al. |
Safety review: squalene and thimerosal in vaccines. |
2010 Nov-Dec |
Therapie |
pmid:21176760
|
Montagnani S et al. |
Autoimmune hemolytic anemia following MF59-adjuvanted influenza vaccine administration: a report of two cases. |
2011 |
Ann Pharmacother |
pmid:21189364
|
Esposito S et al. |
Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents. |
2011 |
Vaccine |
pmid:21199699
|
van den Brand JM et al. |
Efficacy of vaccination with different combinations of MF59-adjuvanted and nonadjuvanted seasonal and pandemic influenza vaccines against pandemic H1N1 (2009) influenza virus infection in ferrets. |
2011 |
J. Virol. |
pmid:21209108
|
Calabro S et al. |
Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. |
2011 |
Vaccine |
pmid:21215831
|
Sarpietro MG et al. |
Synthesis of n-squalenoyl cytarabine and evaluation of its affinity with phospholipid bilayers and monolayers. |
2011 |
Int J Pharm |
pmid:21219999
|
Alghisi F et al. |
Immunogenicity and safety profile of the monovalent A/H1N1 MF59-adjuvanted vaccine in patients affected by cystic fibrosis. |
2011 |
Thorax |
pmid:21228426
|
Durando P et al. |
Adjuvants and alternative routes of administration towards the development of the ideal influenza vaccine. |
2011 Jan-Feb |
Hum Vaccin |
pmid:21245655
|
Schellenberger MT et al. |
Evaluation of adjuvants for a candidate conjugate vaccine against benzo[a]pyrene. |
2011 Jan-Feb |
Hum Vaccin |
pmid:21245662
|
Brasser AJ et al. |
Presence of wax esters and squalene in human saliva. |
2011 |
Arch. Oral Biol. |
pmid:21247555
|
Morel S et al. |
Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity. |
2011 |
Vaccine |
pmid:21256188
|
Lama-Muñoz A et al. |
New hydrothermal treatment of alperujo enhances the content of bioactive minor components in crude pomace olive oil. |
2011 |
J. Agric. Food Chem. |
pmid:21265536
|
Ellebedy AH et al. |
Inflammasome-independent role of the apoptosis-associated speck-like protein containing CARD (ASC) in the adjuvant effect of MF59. |
2011 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:21270336
|
Decaro N et al. |
Immunogenicity and protective efficacy in dogs of an MF59â„¢-adjuvanted vaccine against recombinant canine/porcine coronavirus. |
2011 |
Vaccine |
pmid:21272607
|
Arias JL et al. |
Squalene based nanocomposites: a new platform for the design of multifunctional pharmaceutical theragnostics. |
2011 |
ACS Nano |
pmid:21275408
|
Arguedas A et al. |
Assessment of the safety, tolerability and kinetics of the immune response to A/H1N1v vaccine formulations with and without adjuvant in healthy pediatric subjects from 3 through 17 years of age. |
2011 |
Hum Vaccin |
pmid:21285531
|
Manuel O et al. |
Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients. |
2011 |
Clin. Infect. Dis. |
pmid:21288852
|
Beran J et al. |
A phase III, randomized, open-label study to assess the tolerability and immunogenicity of an H5N1 influenza vaccine administered to healthy adults with a 1-, 2-, 3-, or 6-week interval between first and second doses. |
2010 |
Clin Ther |
pmid:21316535
|
Fabbiani M et al. |
Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients. |
2011 |
Vaccine |
pmid:21349364
|
Gill S et al. |
Cholesterol-dependent degradation of squalene monooxygenase, a control point in cholesterol synthesis beyond HMG-CoA reductase. |
2011 |
Cell Metab. |
pmid:21356516
|
Lens M and Podesta Marty MH |
Assessment of the kinetics of the antioxidative capacity of topical antioxidants. |
2011 |
J Drugs Dermatol |
pmid:21369642
|
Cristiani C et al. |
Safety of MF-59 adjuvanted vaccine for pandemic influenza: results of the vaccination campaign in an Italian health district. |
2011 |
Vaccine |
pmid:21396903
|
Parretta E et al. |
Italian post-marketing surveillance for adverse event reports after MF59-adjuvanted H1N1v vaccination. |
2011 |
Vaccine |
pmid:21406267
|
Ambike A et al. |
Interaction of self-assembled squalenoyl gemcitabine nanoparticles with phospholipid-cholesterol monolayers mimicking a biomembrane. |
2011 |
Langmuir |
pmid:21413743
|
Sun Y et al. |
A reproducible in-vivo model of lymphatic malformation in rats. |
2011 |
J. Comp. Pathol. |
pmid:21419420
|
Meier S et al. |
Antibody responses to natural influenza A/H1N1/09 disease or following immunization with adjuvanted vaccines, in immunocompetent and immunocompromised children. |
2011 |
Vaccine |
pmid:21419775
|
Réjiba S et al. |
Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer. |
2011 |
Nanomedicine |
pmid:21419876
|
Banzhoff A et al. |
Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations. |
2011 |
Hum Vaccin |
pmid:21422814
|
Tabache F et al. |
Acute polyarthritis after influenza A (H1N1) immunization. |
2011 |
Joint Bone Spine |
pmid:21444232
|
Liu CL et al. |
The direct observation of secondary radical chain chemistry in the heterogeneous reaction of chlorine atoms with submicron squalane droplets. |
2011 |
Phys Chem Chem Phys |
pmid:21455529
|
Esposito S et al. |
Influenza A/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23 months. |
2011 |
Pediatrics |
pmid:21464195
|
Gao J et al. |
Laser-induced acoustic desorption/atmospheric pressure chemical ionization mass spectrometry. |
2011 |
J. Am. Soc. Mass Spectrom. |
pmid:21472571
|
Weschler CJ et al. |
Squalene and cholesterol in dust from danish homes and daycare centers. |
2011 |
Environ. Sci. Technol. |
pmid:21476540
|
Cauda V et al. |
"Liquid-phase calcination" of colloidal mesoporous silica nanoparticles in high-boiling solvents. |
2011 |
J. Am. Chem. Soc. |
pmid:21480591
|
Griffiths PD et al. |
Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. |
2011 |
Lancet |
pmid:21481708
|
Vidal C et al. |
Seborrheic dermatitis and HIV infection. Qualitative analysis of skin surface lipids in men seropositive and seronegative for HIV. |
1990 |
J. Am. Acad. Dermatol. |
pmid:2148754
|
Stone HD and Xie ZX |
Efficacy of experimental Newcastle disease water-in-oil oil-emulsion vaccines formulated from squalane and squalene. |
1990 Oct-Dec |
Avian Dis. |
pmid:2149264
|
Inagaki YS et al. |
Investigation of the potential for triterpene synthesis in rice through genome mining and metabolic engineering. |
2011 |
New Phytol. |
pmid:21501172
|
Garcia-Sicilia J et al. |
Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents. |
2011 |
Vaccine |
pmid:21504774
|
Yockel S and Schatz GC |
Dynamic QM/MM: a hybrid approach to simulating gas-liquid interactions. |
2012 |
Top Curr Chem |
pmid:21506003
|
O'Hagan DT et al. |
MF59 adjuvant: the best insurance against influenza strain diversity. |
2011 |
Expert Rev Vaccines |
pmid:21506643
|
Esposito S et al. |
Immunogenicity, safety and tolerability of monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in children and adolescents with Williams or Cornelia De Lange syndrome. |
2011 |
Hum Vaccin |
pmid:21508673
|
AÄimoviÄ J et al. |
Circadian rhythm of cholesterol synthesis in mouse liver: a statistical analysis of the post-squalene metabolites in wild-type and Crem-knock-out mice. |
2011 |
Biochem. Biophys. Res. Commun. |
pmid:21531203
|
Siedenburg G and Jendrossek D |
Squalene-hopene cyclases. |
2011 |
Appl. Environ. Microbiol. |
pmid:21531832
|
Tsai TF et al. |
Explorations of clinical trials and pharmacovigilance databases of MF59®-adjuvanted influenza vaccines for associated cases of narcolepsy. |
2011 |
Scand. J. Infect. Dis. |
pmid:21534891
|
Kozlov VG and Viktorova EG |
[Evaluation of the efficiency and reactogenicity of emulsion-based adjuvant systems in the manufacture of polyclonal enteroviral diagnostic sera]. |
2011 Mar-Apr |
Vopr. Virusol. |
pmid:21545042
|
Zhang LW et al. |
Oil components modulate the skin delivery of 5-aminolevulinic acid and its ester prodrug from oil-in-water and water-in-oil nanoemulsions. |
2011 |
Int J Nanomedicine |
pmid:21556344
|
Raouane M et al. |
Synthesis, characterization, and in vivo delivery of siRNA-squalene nanoparticles targeting fusion oncogene in papillary thyroid carcinoma. |
2011 |
J. Med. Chem. |
pmid:21561161
|
Nowosielski M and Hoffmann M |
Do the substituent effects affect conformational freedom of squalene in hopene biosynthesis? |
2011 |
J Mol Model |
pmid:21562825
|
Lopez P et al. |
Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized, controlled trial of immunogenicity and safety in healthy adults. |
2011 |
J. Infect. Dis. |
pmid:21606530
|
Cen-Pacheco F et al. |
Cytotoxic oxasqualenoids from the red alga Laurencia viridis. |
2011 |
Eur J Med Chem |
pmid:21616566
|
Launay O et al. |
Safety and immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trial. |
2011 |
J. Infect. Dis. |
pmid:21628666
|
Khurana S et al. |
MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. |
2011 |
Sci Transl Med |
pmid:21632986
|
Hirayama C et al. |
Serum cholesterol and squalene in hepatocellular carcinoma. |
1979 |
Clin. Chim. Acta |
pmid:216506
|
Seubert A et al. |
Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88. |
2011 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:21690334
|
Piccialli V et al. |
Isolation of a bis-iodurated tetra-THF as a trace product from the oxidation of squalene with RuOâ‚„ and its double ring expansion to a novel bis-THF-bis-THP compound. |
2011 |
Molecules |
pmid:21709619
|
Iannazzo S |
Pharmacoeconomic evaluation of the MF59--adjuvanted influenza vaccine in the elderly population in Italy. |
2011 |
J Prev Med Hyg |
pmid:21710816
|
Cheong HJ et al. |
Immunogenicity and safety of the influenza A/H1N1 2009 inactivated split-virus vaccine in young and older adults: MF59-adjuvanted vaccine versus nonadjuvanted vaccine. |
2011 |
Clin. Vaccine Immunol. |
pmid:21715575
|
Brito LA et al. |
An alternative renewable source of squalene for use in emulsion adjuvants. |
2011 |
Vaccine |
pmid:21723355
|
Okike IO et al. |
The immunogenicity of a novel A (H1N1) vaccine in HIV-infected children. |
2011 |
Vaccine |
pmid:21742005
|
Niehaus TD et al. |
Identification of unique mechanisms for triterpene biosynthesis in Botryococcus braunii. |
2011 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:21746901
|
Mackay D and Jones PJ |
Evaluation of methods for the determination of cholesterol absorption and synthesis in humans. |
2011 |
Atherosclerosis |
pmid:21763652
|
Jawaid AM et al. |
Shape-controlled colloidal synthesis of rock-salt lead selenide nanocrystals. |
2011 |
ACS Nano |
pmid:21770427
|
Narayan BH et al. |
Modulation of doxorubicin-induced genotoxicity by squalene in Balb/c mice. |
2010 |
Food Funct |
pmid:21776469
|
Kowert BA and Watson MB |
Diffusion of organic solutes in squalane. |
2011 |
J Phys Chem B |
pmid:21780767
|
Bildstein L et al. |
Interaction of an amphiphilic squalenoyl prodrug of gemcitabine with cellular membranes. |
2011 |
Eur J Pharm Biopharm |
pmid:21784150
|
Viganò A et al. |
Long-term immunogenicity after one and two doses of a monovalent MF59-adjuvanted A/H1N1 Influenza virus vaccine coadministered with the seasonal 2009-2010 nonadjuvanted Influenza virus vaccine in HIV-infected children, adolescents, and young adults in a randomized controlled trial. |
2011 |
Clin. Vaccine Immunol. |
pmid:21795458
|
Huijskens E et al. |
Immunogenicity, boostability, and sustainability of the immune response after vaccination against Influenza A virus (H1N1) 2009 in a healthy population. |
2011 |
Clin. Vaccine Immunol. |
pmid:21795459
|
Pollard AJ and Hill AV |
Antibody repertoire: embracing diversity. |
2011 |
Sci Transl Med |
pmid:21795586
|
Oliaro-Bosso S et al. |
Characterization of the channel constriction allowing the access of the substrate to the active site of yeast oxidosqualene cyclase. |
2011 |
PLoS ONE |
pmid:21811565
|
Desmaële D et al. |
Squalenoylation: a generic platform for nanoparticular drug delivery. |
2012 |
J Control Release |
pmid:21840355
|
Andrews NJ et al. |
Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines. |
2011 |
Vaccine |
pmid:21875635
|
Meyer K et al. |
A weak neutralizing antibody response to hepatitis C virus envelope glycoprotein enhances virus infection. |
2011 |
PLoS ONE |
pmid:21887300
|
Della Cioppa G et al. |
Trivalent and quadrivalent MF59(®)-adjuvanted influenza vaccine in young children: a dose- and schedule-finding study. |
2011 |
Vaccine |
pmid:21906647
|
Fox CB et al. |
Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions. |
2011 |
Vaccine |
pmid:21906648
|
Soto G et al. |
Acetoacetyl-CoA thiolase regulates the mevalonate pathway during abiotic stress adaptation. |
2011 |
J. Exp. Bot. |
pmid:21908473
|
Zuccotti GV et al. |
Long-lasting immunogenicity and safety of a 2009 pandemic influenza A(H1N1) MF59-adjuvanted vaccine when co-administered with a 2009-2010 seasonal influenza vaccine in young patients with type 1 diabetes mellitus. |
2011 |
Diabet. Med. |
pmid:21916971
|
Broeders NE et al. |
Influenza A/H1N1 vaccine in patients treated by kidney transplant or dialysis: a cohort study. |
2011 |
Clin J Am Soc Nephrol |
pmid:21921153
|
Achiraman S et al. |
Increased squalene concentrations in the clitoral gland during the estrous cycle in rats: an estrus-indicating scent mark? |
2011 |
Theriogenology |
pmid:21924481
|
Precioso AR et al. |
A phase I randomized, double-blind, controlled trial of 2009 influenza A (H1N1) inactivated monovalent vaccines with different adjuvant systems. |
2011 |
Vaccine |
pmid:21945258
|
Pariani E et al. |
Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy. |
2011 |
Vaccine |
pmid:21974995
|